TERMOFARMA
ActiveSummary
TERMOFARMA has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.2m and a net result of €131,866. Equity is growing by about 9.7% per year across the filed financial years. Its solvency ranks better than 56% of 10,686 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 18 days late
2025
28-08
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format · 28 days late
2024
28-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 28 days late
2023
31-12
Financial
Equity above €2mequity €2.1m ▲7.4%
A profit in every financial year since 2018 builds equity to €2.1m.
29-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 29 days late
2022
26-08
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 26 days late
2021
30-08
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format · 30 days late
2020
31-12
Financial
Highest result from 2018 to 2025net €445,203 ▲315%
Net result €445,203, the highest in the series.
28-08
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format · 28 days late
2019
27-08
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format · 27 days late
2018
27-08
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format · 27 days late
2017
30-08
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 16 annual accounts filed, the latest 10 are here; all 16 are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.